Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan

Michiko Kida, Kensuke Usuki, Naoyuki Uchida, Takahiro Fukuda, Yuta Katayama, Tadakazu Kondo, Tetsuya Eto, Ken ichi Matsuoka, Yoshiko Matsuhashi, Shuichi Ota, Masashi Sawa, Toshihiro Miyamoto, Tatsuo Ichinohe, Takafumi Kimura, Yoshiko Atsuta, Akiyoshi Takami, Yasushi Miyazaki, Shingo Yano, Ken Ishiyama, Masamitsu YanadaJun Aoki

Research output: Contribution to journalArticle

Abstract

This study aimed to investigate allogeneic hematopoietic cell transplantation (HCT) outcomes and risk factors in adult patients with therapy-related myeloid neoplasm (t-MN) using Japanese registry data. Between 2002 and 2012, a total 12,169 adult patients underwent HCT for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). Of these, 565 with t-MN were identified. The median patient age was 54 years (range, 16 to 80 years). Three hundred and ninety-eight patients had AML, 154 had MDS, and 13 had CMML. Lymphoma and breast cancer were the major previous malignancies. Favorable karyotypes were detected in 84 patients, and poor karyotypes were identified in 235. Two-thirds (66%) of the patients were in nonremission at HCT. Overall survival at 3 years in patients with t-MN was 31% (95% confidence interval [CI], 27% to 35%), equivalent to that in those with secondary MN (32%; 95% CI, 30% to 34%), and 44% in the de novo cohort (95% CI, 43% to 45%). The cumulative incidence of relapse and nonrelapse mortality at 3 years was 40% and 33%, respectively. The outcomes of HCT for t-MN in Japan were comparable to those in large-scale studies in Europe and the United States.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - Jan 1 2020

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan'. Together they form a unique fingerprint.

  • Cite this

    Kida, M., Usuki, K., Uchida, N., Fukuda, T., Katayama, Y., Kondo, T., Eto, T., Matsuoka, K. I., Matsuhashi, Y., Ota, S., Sawa, M., Miyamoto, T., Ichinohe, T., Kimura, T., Atsuta, Y., Takami, A., Miyazaki, Y., Yano, S., Ishiyama, K., ... Aoki, J. (Accepted/In press). Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2020.04.004